Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CD44_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CD44_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CD44_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CD44_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CD44_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CD44_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CD44_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CD44_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CD44_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CD44_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CD44_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CD44_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00975813 | Colorectum | MSI-H | lamellipodium organization | 15/1319 | 90/18723 | 1.48e-03 | 2.23e-02 | 15 |
GO:20010203 | Colorectum | MSI-H | regulation of response to DNA damage stimulus | 28/1319 | 219/18723 | 1.60e-03 | 2.39e-02 | 28 |
GO:19021651 | Colorectum | MSI-H | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 5/1319 | 16/18723 | 3.90e-03 | 4.51e-02 | 5 |
GO:00226044 | Colorectum | FAP | regulation of cell morphogenesis | 87/2622 | 309/18723 | 4.89e-11 | 1.87e-08 | 87 |
GO:00315893 | Colorectum | FAP | cell-substrate adhesion | 93/2622 | 363/18723 | 2.48e-09 | 4.61e-07 | 93 |
GO:00420604 | Colorectum | FAP | wound healing | 99/2622 | 422/18723 | 9.50e-08 | 6.33e-06 | 99 |
GO:00071603 | Colorectum | FAP | cell-matrix adhesion | 63/2622 | 233/18723 | 1.13e-07 | 7.43e-06 | 63 |
GO:00975814 | Colorectum | FAP | lamellipodium organization | 29/2622 | 90/18723 | 8.11e-06 | 2.40e-04 | 29 |
GO:19027434 | Colorectum | FAP | regulation of lamellipodium organization | 20/2622 | 54/18723 | 2.09e-05 | 5.05e-04 | 20 |
GO:00181053 | Colorectum | FAP | peptidyl-serine phosphorylation | 71/2622 | 315/18723 | 2.51e-05 | 5.82e-04 | 71 |
GO:00971934 | Colorectum | FAP | intrinsic apoptotic signaling pathway | 66/2622 | 288/18723 | 2.76e-05 | 6.33e-04 | 66 |
GO:00457854 | Colorectum | FAP | positive regulation of cell adhesion | 92/2622 | 437/18723 | 3.09e-05 | 7.04e-04 | 92 |
GO:00182092 | Colorectum | FAP | peptidyl-serine modification | 73/2622 | 338/18723 | 8.47e-05 | 1.51e-03 | 73 |
GO:20010204 | Colorectum | FAP | regulation of response to DNA damage stimulus | 51/2622 | 219/18723 | 1.40e-04 | 2.21e-03 | 51 |
GO:20012334 | Colorectum | FAP | regulation of apoptotic signaling pathway | 74/2622 | 356/18723 | 2.65e-04 | 3.60e-03 | 74 |
GO:20012424 | Colorectum | FAP | regulation of intrinsic apoptotic signaling pathway | 39/2622 | 164/18723 | 5.21e-04 | 5.91e-03 | 39 |
GO:00432814 | Colorectum | FAP | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 46/2622 | 209/18723 | 1.06e-03 | 1.03e-02 | 46 |
GO:20001164 | Colorectum | FAP | regulation of cysteine-type endopeptidase activity | 50/2622 | 235/18723 | 1.45e-03 | 1.31e-02 | 50 |
GO:00723314 | Colorectum | FAP | signal transduction by p53 class mediator | 37/2622 | 163/18723 | 1.76e-03 | 1.53e-02 | 37 |
GO:00525474 | Colorectum | FAP | regulation of peptidase activity | 86/2622 | 461/18723 | 2.98e-03 | 2.27e-02 | 86 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD44 | SNV | Missense_Mutation | | c.106G>A | p.Val36Met | p.V36M | P16070 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
CD44 | SNV | Missense_Mutation | novel | c.1934C>T | p.Pro645Leu | p.P645L | P16070 | protein_coding | deleterious(0) | possibly_damaging(0.541) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CD44 | SNV | Missense_Mutation | | c.829G>C | p.Glu277Gln | p.E277Q | P16070 | protein_coding | tolerated(0.18) | benign(0.32) | TCGA-D8-A143-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CD44 | insertion | Nonsense_Mutation | novel | c.1935_1936insATCATATAATCTCAATGCAATAAATAATCAA | p.Gln646IlefsTer3 | p.Q646Ifs*3 | P16070 | protein_coding | | | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CD44 | deletion | Frame_Shift_Del | | c.1454_1461delCAAATCCA | p.Ala485GlufsTer22 | p.A485Efs*22 | P16070 | protein_coding | | | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD44 | SNV | Missense_Mutation | novel | c.476N>C | p.Gly159Ala | p.G159A | P16070 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
CD44 | SNV | Missense_Mutation | | c.1521N>C | p.Gln507His | p.Q507H | P16070 | protein_coding | deleterious(0.02) | possibly_damaging(0.707) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
CD44 | SNV | Missense_Mutation | rs371026548 | c.1289C>T | p.Ser430Leu | p.S430L | P16070 | protein_coding | deleterious(0.02) | benign(0.154) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CD44 | SNV | Missense_Mutation | novel | c.1790N>C | p.Asn597Thr | p.N597T | P16070 | protein_coding | deleterious(0.01) | benign(0.025) | TCGA-VS-A9U5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CD44 | SNV | Missense_Mutation | | c.92N>T | p.Ala31Val | p.A31V | P16070 | protein_coding | deleterious(0) | benign(0.329) | TCGA-AA-A01I-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | GENTAMICIN | GENTAMICIN | 14967965 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | MPA | PROGESTERONE | 11605071 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | RG7356 | | 25762343 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | TUMOR NECROSIS FACTOR | | 12867430 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | GP-120 | | 7539755 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | INTERFERON GAMMA | | 11369659 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | HYALURONAN | HYALURONAN | |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | MOMETASONE FUROATE | | 12877820 |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | A-6 | | |
960 | CD44 | DRUGGABLE GENOME, CELL SURFACE | | BIWA 4 | | |